Shire Licenses Sangamo’s Genome-Editing Technology for Haemophilia and Other Monogenic Diseases

By Heather Cartwright

PharmaDeals Review: Vol 2012 Issue 2 (Table of Contents)

Published: 20 Feb-2012

DOI: 10.3833/pdr.v2012.i2.1687     ISSN: 1756-7874

Section: Research & Development

Fulltext:

Abstract

Shire has agreed to pay Sangamo BioSciences US$13 M upfront for the global rights to use the company’s zinc finger DNA-binding protein (ZFP) technology platform to develop therapies for haemophilia and other monogenic diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: PharmaDeals Ltd

Bookmarks

Bookmark PharmaDeals through one of these social networks.